How should completely resected stage II-III with activating EGFR mutation be treated? ongoing studies

Date 16 April 2015
Event ELCC 2015
Session Oncogene-driven early stage NSCLC
Topics Anti-Cancer Agents & Biologic Therapy
Non-Small-Cell Lung Cancer, Early Stage
Translational Research
Presenter Mark Kris
Authors M. Kris
  • Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York/US